Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark'
October 15, 2014 at 16:42 PM EDT
Johnson & Johnson's (NYSE: JNJ) new hepatitis C drug Olysio helped it beat third quarter Street views, but an analyst ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
